{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T18:28:26Z","timestamp":1655490506209},"reference-count":118,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.cll.2011.08.009","type":"journal-article","created":{"date-parts":[[2011,11,30]],"date-time":"2011-11-30T18:20:16Z","timestamp":1322677216000},"page":"699-724","source":"Crossref","is-referenced-by-count":6,"title":["Multiple Myeloma: Current Perspectives"],"prefix":"10.1016","volume":"31","author":[{"given":"Marilyn L.","family":"Slovak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cll.2011.08.009_bib1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cll.2011.08.009_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0959-8049(01)00350-1","article-title":"Estimates of cancer incidence and mortality in Europe in 1995","volume":"38","author":"Bray","year":"2002","journal-title":"Eur J Cancer"},{"issue":"Suppl 12","key":"10.1016\/j.cll.2011.08.009_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ijc.22718","article-title":"Multiple myeloma: a review of the epidemiologic literature","volume":"120","author":"Alexander","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cll.2011.08.009_bib4","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib5","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib6","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2010-10-299529","article-title":"Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3","volume":"117","author":"Dimopoulos","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib8","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1158\/1078-0432.CCR-10-1822","article-title":"From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention","volume":"17","author":"Landgren","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cll.2011.08.009_bib9","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1182\/blood-2007-02-069625","article-title":"Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma","volume":"110","author":"Gonzalez","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib10","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib11","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1038\/sj.onc.1204641","article-title":"Chromosome translocations in multiple myeloma","volume":"20","author":"Bergsagel","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.cll.2011.08.009_bib12","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib13","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.ejca.2006.01.065","article-title":"Epidemiology and outcomes research for MGUS, myeloma and amyloidosis","volume":"42","author":"Sirohi","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cll.2011.08.009_bib14","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/sj.leu.2404573","article-title":"Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide","volume":"21","author":"Prince","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.cll.2011.08.009_bib15","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib16","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1200\/JCO.2010.29.7929","article-title":"International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma","volume":"28","author":"Lokhorst","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cll.2011.08.009_bib17","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib18","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2010-10-300970","article-title":"Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2","volume":"117","author":"Munshi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib19","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1200\/JCO.2008.20.6136","article-title":"Prognostic significance of copy-number alterations in multiple myeloma","volume":"27","author":"Avet-Loiseau","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cll.2011.08.009_bib20","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1182\/blood-2010-04-278788","article-title":"A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression","volume":"117","author":"Annunziata","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood.V66.2.380.380","article-title":"The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis","volume":"66","author":"Dewald","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0165-4608(94)00284-I","article-title":"Cytogenetic findings in 200 patients with multiple myeloma","volume":"82","author":"Sawyer","year":"1995","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cll.2011.08.009_bib23","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1182\/blood.V85.9.2490.bloodjournal8592490","article-title":"Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis","volume":"85","author":"Lai","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib24","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/sj.leu.2401041","article-title":"Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases","volume":"12","author":"Smadja","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.cll.2011.08.009_bib25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0165-4608(99)00009-6","article-title":"Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma","volume":"113","author":"Rajkumar","year":"1999","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cll.2011.08.009_bib26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/(SICI)1098-2264(199702)18:2<84::AID-GCC2>3.0.CO;2-X","article-title":"Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations","volume":"18","author":"Calasanz","year":"1997","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.cll.2011.08.009_bib27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1046\/j.1365-2141.1998.00657.x","article-title":"Prognostic value of cytogenetics in multiple myeloma","volume":"101","author":"Seong","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cll.2011.08.009_bib28","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2005-05-1981","article-title":"Relationship of patient survival and chromosome anomalies detected in metaphase and\/or interphase cells at diagnosis of myeloma","volume":"106","author":"Dewald","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib29","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood-2003-02-0493","article-title":"The recurrent IGH translocations are highly associated with nonhyperdiploid variant multiple myeloma","volume":"102","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib30","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib31","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2006.03.019","article-title":"High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients","volume":"9","author":"Carrasco","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cll.2011.08.009_bib32","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1182\/blood-2007-10-119123","article-title":"An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma","volume":"112","author":"Xiong","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib33","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","article-title":"A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib34","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib35","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","article-title":"Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients","volume":"116","author":"Broyl","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/978-1-61779-074-4_12","article-title":"Detection of chromosome abnormalities using cytoplasmic immunoglobulin staining and FISH in myeloma","volume":"730","author":"Mercer","year":"2011","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.cll.2011.08.009_bib37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cancergencyto.2005.01.006","article-title":"Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype\/genotype fluorescence in situ hybridization","volume":"158","author":"Slovak","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cll.2011.08.009_bib38","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/sj.leu.2402937","article-title":"Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR","volume":"17","author":"Gonzalez","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.cll.2011.08.009_bib39","first-page":"1365","article-title":"Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry","volume":"90","author":"Sarasquete","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.cll.2011.08.009_bib40","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.leu.2403586","article-title":"Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma","volume":"19","author":"Wuilleme","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.cll.2011.08.009_bib41","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/gcc.20231","article-title":"Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics","volume":"44","author":"Cremer","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.cll.2011.08.009_bib42","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.cll.2011.08.009_bib43","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood.V98.7.2229","article-title":"Hypodiploidy is a major prognostic factor in multiple myeloma","volume":"98","author":"Smadja","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib44","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/gcc.10275","article-title":"Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases","volume":"38","author":"Smadja","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.cll.2011.08.009_bib45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cll.2011.08.009_bib46","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/gcc.20563","article-title":"Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors","volume":"47","author":"Gabrea","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.cll.2011.08.009_bib47","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.hoc.2007.08.004","article-title":"Molecular pathogenesis of multiple myeloma","volume":"21","author":"Tonon","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.cll.2011.08.009_bib48","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.cll.2011.08.009_bib49","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/asheducation-2005.1.346","article-title":"Early genetic events provide the basis for a clinical classification of multiple myeloma","author":"Kuehl","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.cll.2011.08.009_bib50","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1182\/blood-2002-06-1675","article-title":"In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression","volume":"101","author":"Keats","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib51","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood-2002-09-2801","article-title":"A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH\/MMSET fusion transcript","volume":"101","author":"Santra","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib52","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1182\/blood.V99.6.2185","article-title":"Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation","volume":"99","author":"Avet-Loiseau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib53","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3109\/10428194.2010.537795","article-title":"Clinical and biological features of t(4;14) multiple myeloma: a prospective study","volume":"52","author":"Karlin","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cll.2011.08.009_bib54","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib55","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.leu.2404413","volume":"21","author":"Gutierrez","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.cll.2011.08.009_bib56","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)","volume":"28","author":"Avet-Loiseau","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cll.2011.08.009_bib57","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1309\/4W8E-8F4K-BHUP-UBE7","article-title":"The (11;14)(q13;q32) translocation in multiple myeloma","volume":"113","author":"Hoyer","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cll.2011.08.009_bib58","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.leu.2403091","article-title":"t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma","volume":"17","author":"Garand","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.cll.2011.08.009_bib59","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib60","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2004-03-0833","article-title":"Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors","volume":"105","author":"Rasmussen","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib61","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/leu.2008.142","article-title":"Clinical and biological significance of RAS mutations in multiple myeloma","volume":"22","author":"Chng","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.cll.2011.08.009_bib62","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V98.1.217","article-title":"Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma","volume":"98","author":"Shaughnessy","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib63","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/mcp.2009.0603","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"84","author":"Kumar","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cll.2011.08.009_bib64","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib65","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3324\/haematol.2009.016329","article-title":"The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance","volume":"95","author":"Ross","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.cll.2011.08.009_bib66","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood-2010-07-295105","article-title":"Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?","volume":"117","author":"Avet-Loiseau","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib67","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1535-6108(04)00019-4","article-title":"Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma","volume":"5","author":"Hurt","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cll.2011.08.009_bib68","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","article-title":"Superior results of Total Therapy 3 (2003\u201333) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006\u201366 with VRD maintenance","volume":"115","author":"Nair","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib69","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1006\/geno.2000.6321","article-title":"The characterization of the common fragile site FRA16D and its involvement in multiple myeloma translocations","volume":"69","author":"Krummel","year":"2000","journal-title":"Genomics"},{"key":"10.1016\/j.cll.2011.08.009_bib70","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood-2007-02-075069","article-title":"Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma","volume":"110","author":"Jenner","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib71","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/gcc.1189","article-title":"Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma","volume":"32","author":"Le Baccon","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.cll.2011.08.009_bib72","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/blood.V91.5.1732","article-title":"Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin","volume":"91","author":"Sawyer","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib73","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/gcc.20109","article-title":"Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q","volume":"42","author":"Sawyer","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.cll.2011.08.009_bib74","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib75","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.bbmt.2007.05.014","article-title":"Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant","volume":"13","author":"Qazilbash","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cll.2011.08.009_bib76","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3816\/CLM.2007.n.003","article-title":"Sequential analysis of chromosome aberrations in multiple myeloma during disease progression","volume":"7","author":"Wu","year":"2007","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.cll.2011.08.009_bib77","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1158\/1078-0432.CCR-08-0347","article-title":"Deletions of CDKN2C in multiple myeloma: biological and clinical implications","volume":"14","author":"Leone","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cll.2011.08.009_bib78","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/bmt.2009.107","article-title":"1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma","volume":"45","author":"Chang","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cll.2011.08.009_bib79","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.3109\/10428194.2010.524325","article-title":"Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone","volume":"51","author":"Chang","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cll.2011.08.009_bib80","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/leu.2010.21","article-title":"Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31\u201332 deletion as a prognostic factor in myeloma","volume":"24","author":"Chng","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.cll.2011.08.009_bib81","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0002-9440(10)63276-2","article-title":"Overexpression of PDZK1 within the 1q12\u2013q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma","volume":"165","author":"Inoue","year":"2004","journal-title":"Am J Pathol"},{"issue":"Suppl 1","key":"10.1016\/j.cll.2011.08.009_bib82","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10245330512331390140","article-title":"Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma","volume":"10","author":"Shaughnessy","year":"2005","journal-title":"Hematology"},{"key":"10.1016\/j.cll.2011.08.009_bib83","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1182\/blood-2006-07-038703","article-title":"CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib84","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2141.2005.05673.x","article-title":"Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma","volume":"130","author":"Rosinol","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cll.2011.08.009_bib85","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","article-title":"Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma","volume":"20","author":"Fonseca","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.cll.2011.08.009_bib86","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bbmt.2009.11.025","article-title":"Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy","volume":"16","author":"Nemec","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cll.2011.08.009_bib87","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood.V98.10.3082","article-title":"Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors","volume":"98","author":"Avet-Loiseau","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib88","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.97.1.228","article-title":"Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma","volume":"97","author":"Shou","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cll.2011.08.009_bib89","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1046\/j.1365-2141.2003.04260.x","article-title":"CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease","volume":"121","author":"Guikema","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cll.2011.08.009_bib90","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1365-2141.2005.05849.x","article-title":"Lack of CD27 in myeloma delineates different presentation and outcome","volume":"132","author":"Moreau","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cll.2011.08.009_bib91","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1309\/ELGMGX81C2UTP55R","article-title":"Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis","volume":"126","author":"Morgan","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cll.2011.08.009_bib92","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V96.4.1505","article-title":"High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH","volume":"96","author":"Shaughnessy","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib93","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1182\/blood.V95.6.1925","article-title":"Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization","volume":"95","author":"Zojer","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib94","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2009.011064","article-title":"Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context","volume":"94","author":"Chiecchio","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.cll.2011.08.009_bib95","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0014-5793(98)00357-3","article-title":"A cosmid and cDNA fine physical map of a human chromosome 13q14 region frequently lost in B-cell chronic lymphocytic leukemia and identification of a new putative tumor suppressor gene, Leu5","volume":"426","author":"Kapanadze","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1016\/j.cll.2011.08.009_bib96","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V92.3.802","article-title":"Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy","volume":"92","author":"Drach","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib97","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2004-04-1363","article-title":"p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation","volume":"105","author":"Chang","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib98","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1365-2141.1999.01615.x","article-title":"P53 deletion is not a frequent event in multiple myeloma","volume":"106","author":"Avet-Loiseau","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cll.2011.08.009_bib99","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood.V81.1.128.128","article-title":"p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy","volume":"81","author":"Neri","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib100","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.beha.2007.08.005","article-title":"Role of genetics in prognostication in myeloma","volume":"20","author":"Avet-Loiseau","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.cll.2011.08.009_bib101","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/asheducation-2010.1.489","article-title":"Ultra high-risk myeloma","volume":"2010","author":"Avet-Loiseau","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.cll.2011.08.009_bib102","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood-2008-12-193458","article-title":"Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13","volume":"114","author":"Reece","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib103","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/leu.2010.175","article-title":"Treatment of patients with relapsed\/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies","volume":"24","author":"Dimopoulos","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.cll.2011.08.009_bib104","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/cncr.25775","article-title":"Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone","volume":"117","author":"Klein","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.cll.2011.08.009_bib105","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2141.1996.d01-1891.x","article-title":"Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma","volume":"95","author":"Govindarajan","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cll.2011.08.009_bib106","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/gcc.20078","article-title":"MDS\/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q)","volume":"41","author":"Nilsson","year":"2004","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.cll.2011.08.009_bib107","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1046\/j.1365-2141.2003.04455.x","article-title":"MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1\u2013year survival despite tandem transplants","volume":"122","author":"Jacobson","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cll.2011.08.009_bib108","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2007-06-097444","article-title":"Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989","volume":"111","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib109","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","article-title":"Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome","volume":"26","author":"Decaux","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cll.2011.08.009_bib110","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","article-title":"Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma","volume":"12","author":"Annunziata","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cll.2011.08.009_bib111","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cll.2011.08.009_bib112","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/blood-2009-09-243535","article-title":"Classical and\/or alternative NF-kappaB pathway activation in multiple myeloma","volume":"115","author":"Demchenko","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib113","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.cll.2011.08.009_bib114","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-10-1843","article-title":"Genomics in multiple myeloma","volume":"17","author":"Munshi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cll.2011.08.009_bib115","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/leu.2009.274","article-title":"Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling","volume":"24","author":"Gutierrez","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.cll.2011.08.009_bib116","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.2010.28.0792","article-title":"Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma","volume":"29","author":"Johnson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cll.2011.08.009_bib117","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1182\/blood-2002-09-2873","article-title":"Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression","volume":"101","author":"Shaughnessy","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cll.2011.08.009_bib118","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3","volume":"138","author":"Barlogie","year":"2007","journal-title":"Br J Haematol"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271211000758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271211000758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T02:55:48Z","timestamp":1593312948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271211000758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":118,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0272271211000758"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2011.08.009","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}